Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBIT (2022 - 2026)

Core Laboratories filings provide 5 years of EBIT readings, the most recent being $1.9 million for Q1 2026.

  • On a quarterly basis, EBIT fell 57.28% to $1.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.1 million, a 86.93% decrease, with the full-year FY2025 number at $9.6 million, down 83.54% from a year prior.
  • EBIT hit $1.9 million in Q1 2026 for Core Laboratories, up from -$31.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $20.9 million in Q3 2025 to a low of -$31.9 million in Q4 2023.
  • Median EBIT over the past 5 years was $14.4 million (2022), compared with a mean of $7.5 million.
  • Biggest five-year swings in EBIT: skyrocketed 144.4% in 2024 and later tumbled 318.7% in 2025.
  • Core Laboratories' EBIT stood at $15.6 million in 2022, then plummeted by 304.38% to -$31.9 million in 2023, then soared by 144.4% to $14.2 million in 2024, then tumbled by 318.7% to -$31.0 million in 2025, then soared by 106.09% to $1.9 million in 2026.
  • The last three reported values for EBIT were $1.9 million (Q1 2026), -$31.0 million (Q4 2025), and $20.9 million (Q3 2025) per Business Quant data.